Provider review
Belle Health Review: A Wide Peptide Range and Very Few Claims
Belle Health prices five compounded peptides openly — semaglutide, tirzepatide, sermorelin, NAD+ and glutathione — and makes essentially no efficacy claim for any of them. On a class of compound where the marketing usually outruns the evidence by a wide margin, saying nothing is the more defensible position, and it is what Belle does.
Sells four compounds whose evidence bases are thin and claims almost nothing for any of them — which, on this class of product, is the right answer. Its prices are all public before you answer anything, and since 14 August it has started naming the pharmacies behind each product too.
Worth trusting if
- You want peptides priced openly without an efficacy pitch attached
- You want compounded and FDA-approved options labeled as what they are
- You already know what the evidence for sermorelin and NAD+ does and does not show
Be skeptical if
- You want to choose the pharmacy yourself — Belle names ten partners but routes your prescription to whichever one is best positioned to fill it
- You want a certificate of analysis
- You want the company to tell you what its longevity peptides actually do — it will not
Compounded only
Phase 3 trials
Named
February 2026
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.joinbelle.com. A link is not a recommendation to take anything.
Provenance
What Belle Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — Read 2026-08-10 as one standing figure with a starter-dose rate beside it. Re-read 2026-08-25: the card is a ladder, and the rung you get depends on how much you buy at once — $199/mo for one month, $135/mo on a two-month supply, $119/mo on six months. The advertised "starting at" figure across the site is the six-month rung. All of it is public before any question is asked, which is more than most of this market manages.
- Sermorelin — $119/mo on a three-month supply, daily injection, priced on the same public table as the GLP-1s. Re-read 2026-08-25: no shorter term is offered for this one, so three months is the only way to buy it.
- NAD+ — Re-read 2026-08-25 with the term attached to each figure, because the term is what moves it: NAD+ is $149/mo on a three-month supply and $199/mo for a single month. Glutathione is $119/mo on two months. MIC+B12 is $65/mo on three months and $99/mo on one. A compounded tirzepatide microdose sits on the same longevity shelf at $99/mo, three-month supply only.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Belle Health.
1
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Belle Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)Claim matches the trials
“Compounded Semaglutide Weight Loss GLP-1 Weekly injection $119/mo Compounded. New to GLP-1s (starter-dose only). Reg $219. […] Compounded GLP-1 medications are prepared for you by licensed compounding pharmacies in the United States, based on your provider's prescription.”
Read on the Belle Health site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — roughly 14.9% mean weight loss from baseline against 2.4% on placebo.
Belle makes no efficacy claim for this product at all — the listing is a product name, a route, a price and the word “Compounded”. There is no percentage, no trial reference and no comparison to Wegovy or Ozempic, which is unusual and means there is nothing here that overstates the evidence. Semaglutide's own phase 3 weight-loss record is real. What Belle does say elsewhere is accurate and worth crediting: it labels the branded rows on the same table “FDA-approved” and the compounded ones “Compounded”, which is the distinction most of this category blurs.1
SermorelinSermorelin · Compounded (503A)Claim matches the trials
“Sermorelin Longevity Growth hormone peptide Daily injection $119/mo Compounded”
Read on the Belle Health site, August 2026
No trial for this use
What the trials show for Sermorelin
As of 2026-08-14 a read of its own site returned no trial, no endpoint and no outcome claim for sermorelin — the listing is a name, a route, a price and the phrase “Growth hormone peptide”. Sermorelin has a human record as a diagnostic and pediatric agent; what it does not have is trial evidence for the longevity and body-composition uses this category sells it for, and Belle claims none.
There is no claim to check, which is the point. Belle describes sermorelin in six words — “Longevity”, “Growth hormone peptide”, “Daily injection” — and asserts no outcome. It does not say it builds muscle, improves recovery, reverses aging or raises IGF-1 to any particular effect. Since the trial evidence for those uses is what does not exist, declining to assert them is the only accurate thing a seller can do. A reader should still understand that “growth hormone peptide” describes a mechanism, not a result.
NAD+NAD+ · Compounded (503A)Claim matches the trials
“NAD+ Longevity Cellular energy cofactor Weekly injection $149/mo Compounded”
Read on the Belle Health site, August 2026
No trial for this use
As of 2026-08-14 a read of its own site returned no trial and no outcome claim for NAD+. It describes it as a “Cellular energy cofactor”, which is a biochemical description rather than a health claim. NAD+ is a real coenzyme with a real role in metabolism; what is absent is trial evidence that injecting it produces the longevity or energy outcomes the category markets.
Again there is no outcome claim to grade. “Cellular energy cofactor” states what NAD+ is in a cell, not what an injection does for a person, and Belle stops there. That is the honest end of a market where NAD+ is routinely sold on promises of energy, focus and reversed aging that no trial supports.
Dispensing chain
Who actually fills your prescription
- BPI Labs — named on the tirzepatide and tirzepatide microdose cards
- Boudreaux — named on the tirzepatide and semaglutide cards
- VialsRx — named on the tirzepatide and semaglutide cards
- ReviveRX — named on the tirzepatide and semaglutide cards
- New Life Rx — named on the tirzepatide card
- Apothecary Pharma — named on the tirzepatide card
- Hyalo Technologies — named on the tirzepatide card
- Olympia Pharmaceuticals — named on the NAD+, glutathione, MIC+B12 and sermorelin cards
- Hallandale — named on the NAD+, glutathione, MIC+B12 and sermorelin cards
- The Pharmacy Hub — named on the two skin products
Read the full account
Re-checked 2026-08-25, and this review previously said no pharmacy was named. That is no longer true, and the change is a real improvement: the pricing page now prints pharmacy names on each product, so a reader can see which compounders sit behind which molecule rather than being told only that they are licensed. Ten names appear across the table. Two things still need care. The FAQ answer to "Which pharmacies fill my prescription?" names four — "BPI Labs, VitalRx Pharmacy, The Pharmacy Hub, and Olympia Pharmaceuticals" — which is a shorter list than the cards carry and spells one of them differently from the card's "VialsRx", so the two lists on one site do not line up. And the routing is not yours to choose: "Your prescription is routed to whichever partner is best positioned to fulfill your specific medication." Belle still says it works with pharmacies that "meet USP-797 sterility standards", and still states under every product image that "Belle is not the compounding pharmacy or manufacturer" — which is precisely what its FDA warning letter found the labels implied.
Read on the Belle Health site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis is published, offered on request, or mentioned. The only quality statement is the USP-797 sterility claim, which describes a standard the pharmacy is said to meet rather than a test result for any batch — and since no pharmacy is named, there is nobody to ask for one.
Read on the Belle Health site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Re-checked 2026-08-25 by walking the signup: the state question inside it says "We currently ship to all 50 U.S. states" and its dropdown lists all fifty plus the District of Columbia, with nothing excluded. That is an answer, and it only appears inside the signup — the public pages still enumerate nothing.
Read the full licensing claim
US-licensed compounding pharmacies that operate under state board oversight and meet USP-797 sterility standards
Read on the Belle Health site, August 2026.
Regulatory
The FDA warning letter
Issued February 2026
Belle Health LLC dba Belle — MARCS-CMS 721795. Concerns marketing and labeling.
Read the full allegation
FDA reviewed the website at https://www.joinbelle.com in December 2025 and cited its representations as false or misleading under FD&C Act sections 502(a) and 502(bb). The letter's single finding: "The compounded semaglutide and tirzepatide products displayed on your website identify 'Belle' on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not." It quotes no advertising copy, makes no allegation about sterility, potency, contamination or any other product-quality matter, and states its citations are "not intended to be an all-inclusive statement of violations."
What has changed since
The site now states plainly, under its product images, that Belle is not the compounding pharmacy or manufacturer — which addresses exactly what the letter found the labels implied. FDA has published no close-out letter.
We did this ourselves
What happens when you sign up with Belle Health
We went through Belle Health’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Press "Get started". First question is what you are here for — weight loss, longevity, or "not sure, help me choose" — and each option lists its own products.
- Pick the specific treatments you want, with a one-line explanation of each.
- Say how much weight you want to lose, from four ranges.
- Say what excites you most about it, from eight options.
- Sex assigned at birth.
- Name, then date of birth, then height, then current weight on a slider.
- Email, then phone with an SMS consent box.
- State — the screen says "We currently ship to all 50 U.S. states" and the dropdown lists fifty plus the District of Columbia.
- Prior GLP-1 use, then current medications entered one by one or "I don't take any medications".
- Allergies, then a specific list of four, then a list of five branded GLP-1s.
- A 13-condition diagnosis checklist, then kidney health, liver health, and diabetes or insulin use.
- Tick an off-label acknowledgment: compounded versions "are not FDA-approved" and may be prescribed "regardless of your BMI".
- More medical screens follow — bariatric surgery, pregnancy. This walk stopped there, roughly 40% along the progress bar, well before payment.
- Every price is public before a single question, on one pricing page, with no email wall. Nine products are listed with a price against each.
- The figure depends on how many months you buy at once. Tirzepatide is $249/mo for one month, $175/mo on a two-month starter bundle marked "starter-dose only" against a regular $219, and $199/mo on six months. Semaglutide runs the same shape.
- The "starting at" figure quoted in the navigation is the six-month rung, so it is the cheapest month rather than the first month.
- Each product names the pharmacies behind it. That is unusual, and it is also two lists: the cards carry ten names, the FAQ answer names four, and one name is spelled differently in each.
- There is no video visit. The FAQ says the intake is written and asynchronous, a provider reviews it and replies by message, "most members hear back from a provider within 24 hours".
- Labs are not routine: "Your provider will request labs only when they're clinically necessary based on your history."
- The intake asks for name, date of birth, height, weight, email and phone before it asks a single medical question.
Belle Health support
- Phone
- 888-541-6003
- care@joinbelle.com
Assessment
What holds up, and what does not
- It makes essentially no efficacy claim for any of its five compounds. On sermorelin and NAD+, where the category's marketing is loudest and the trial evidence thinnest, that restraint is the most defensible position available.
- Compounded and FDA-approved rows are labeled as such on the same table, so the distinction is visible rather than blurred.
- It states outright that “Belle is not the compounding pharmacy or manufacturer”.
Show 3 more
- It names a specific sterility standard — USP-797 — rather than offering a vague assurance about quality.
- Every price is on a public table, so nothing requires an intake to discover.
- Since 14 August it names the pharmacies behind each product on the price card itself — ten of them across the table — which almost nothing else in this market does.
- The two published pharmacy lists disagree: ten names on the price cards, four in the FAQ, and one of them spelled differently in each.
- The price you see is a per-month rate on a multi-month supply, so buying one month at a time costs materially more than the advertised figure.
- No certificate of analysis or test result is published for any compound.
Show 4 more
- Sermorelin and NAD+ are sold under a “Longevity” heading, which implies an outcome the site never claims and no trial supports.
- The state answer is inside the signup rather than on a public page, so you have to start the intake to read it.
- An open FDA warning letter (721795, February 2026) found the product labels pictured on the site implied Belle compounds the drugs itself.
- “Growth hormone peptide” and “Cellular energy cofactor” describe mechanisms, and a reader may take a mechanism for a result.
Verdict
The bottom line
Belle is the rare seller of longevity peptides that does not tell you what they do. That silence is accurate — the trials for those uses do not exist — but it also means the entire case for buying sermorelin or NAD+ here has to come from somewhere other than this company. Ask which pharmacy compounds it before you order.
Opens www.joinbelle.com. A link is not a recommendation to take anything.
What it sells, and what it says about it
Belle Health prices five compounded injectables on one public table: semaglutide, tirzepatide, sermorelin, NAD+, glutathione, plus MIC+B12. Branded Wegovy and Zepbound sit on the same table, labeled FDA-approved, while the compounded rows are labeled Compounded.
That labeling is worth pausing on. The single most common failure in this category is letting a reader believe a compounded preparation is the approved drug. Belle puts the two words in adjacent rows of the same table.
Full analysis — 5 more sectionsThe claims it does not make · The GLP-1s · What is missing · The FDA letter, and what changed · What this means if you are buying
The claims it does not make
Here is the whole of what Belle says about sermorelin:
"Sermorelin — Longevity — Growth hormone peptide — Daily injection — $119/mo — Compounded"
And NAD+:
"NAD+ — Longevity — Cellular energy cofactor — Weekly injection — $149/mo — Compounded"
No percentage. No trial. No outcome. No "improves recovery", no "reverses aging", no "boosts energy".
This matters because sermorelin and NAD+ are the two compounds in this market most routinely sold on promises that no trial supports. Sermorelin has a real human record — as a diagnostic agent and in pediatric growth hormone deficiency — but that record does not extend to the body-composition and longevity uses it is marketed for. NAD+ is a genuine coenzyme with a genuine metabolic role, and "cellular energy cofactor" is an accurate description of what it is in a cell. Neither statement tells you what an injection does for a person, and Belle does not claim to know.
A reader should still supply the missing step themselves: a mechanism is not a result. "Growth hormone peptide" describes what a molecule does at a receptor. Whether that produces anything you would notice is a separate question, and it is the question the trials have not answered.
The GLP-1s
Semaglutide and tirzepatide are different — they have substantial phase 3 evidence behind them for weight loss. 1 2
But the evidence is for the FDA-approved products, and what Belle sells in those rows is compounded. Belle does not blur this: the approved and compounded rows are separately labeled, and it makes no claim that the compounded version performs like the branded one.
What is missing
No pharmacy is named.
Belle says it works exclusively with US-licensed compounding pharmacies under state board oversight meeting USP-797 sterility standards, and has a section headed "Pharmacy Partners". It names none of them. So the sterility standard is asserted rather than attributable, and there is no licensee to look up or ask for a certificate of analysis — none of which is published.
The FDA letter, and what changed
FDA wrote to Belle Health LLC in February 2026. The letter is unusual: it quotes no advertising copy whatsoever. Its single finding is that the products pictured on the site "identify 'Belle' on the pictured label, suggesting Belle is the compounder of those drugs when in fact it is not."
Today, under the product images, the site says: "Belle is not the compounding pharmacy or manufacturer."
That is the letter's complaint answered directly. The letter itself remains open.
What this means if you are buying
If you want a GLP-1, the evidence question is settled for the molecule and open for the preparation, and Belle labels which is which.
If you want sermorelin or NAD+, understand that Belle is not making a case for them and cannot be relied on for one. That is to its credit as a matter of honesty, and it means the reason to buy has to come from somewhere with actual evidence behind it — which, for these uses, does not currently exist.
Questions
Frequently asked questions
What does Belle claim its peptides do?
Almost nothing. Sermorelin is described as a “growth hormone peptide” and NAD+ as a “cellular energy cofactor”, with no outcome, percentage or trial attached to either. Those are descriptions of mechanism, not claims of effect, and on compounds whose trial evidence for these uses does not exist, declining to claim is the accurate position.
Does Belle name its compounding pharmacy?
No. It says it works exclusively with US-licensed compounding pharmacies under state board oversight meeting USP-797 sterility standards, and has a “Pharmacy Partners” section, but names none of them. So neither the license nor the sterility standard can be checked, and there is nobody to request a certificate of analysis from.
Does Belle have an FDA warning letter?
Yes — letter 721795, issued 20 February 2026 and still open. It quotes no advertising copy at all; its single finding is that the product labels pictured on the site implied Belle compounds the drugs itself. The site now states plainly that Belle is not the compounding pharmacy or manufacturer.
Compare
Others selling what Belle Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Belle Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.